Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net sales	$ 4,120	$ 3,599	$ 7,977	$ 6,988
Cost of products sold	1,270	1,058	2,479	2,098
Gross profit	2,850	2,542	5,498	4,891
Operating expenses:
Selling, general and administrative expenses	1,446	1,354	2,810	2,570
Research and development expenses	383	359	749	695
Royalty expense	9	12	19	23
Amortization expense	213	210	427	412
Intangible asset impairment charges	276	57	276	57
Contingent consideration net expense (benefit)	2	19	18	31
Restructuring net charges (credits)	1	16	5	36
Operating expenses	2,330	2,028	4,303	3,825
Operating income (loss)	520	514	1,195	1,066
Other income (expense):
Interest expense	(77)	(70)	(146)	(135)
Other, net	(23)	(18)	(21)	(61)
Income (loss) before income taxes	420	426	1,028	870
Income tax expense (benefit)	98	156	213	287
Net income (loss)	322	270	815	584
Preferred stock dividends	0	(9)	0	(23)
Net income (loss) attributable to noncontrolling interests	(2)	0	(4)	0
Net income (loss) attributable to Boston Scientific common stockholders	$ 324	$ 261	$ 819	$ 561
Net income (loss) per common share — basic	$ 0.22	$ 0.18	$ 0.56	$ 0.39
Net income (loss) per common share — diluted	$ 0.22	$ 0.18	$ 0.55	$ 0.39
Weighted-average shares outstanding
Basic	1,470.6	1,446.2	1,469.5	1,441.0
Diluted	1,484.2	1,456.2	1,483.0	1,451.1